Ozempic, Wegovy and Mounjaro, all GLP-1 anti-obesity medications, may offer health benefits beyond weight loss. Studies show ...
Novo Nordisk’s GLP-1 agonist Ozempic has shown efficacy in yet another indication, achieving a 24% reduction in kidney disease-related events in people with type 2 diabetes and chronic kidney ...
Ozempic is approved for type 2 diabetes, while its counterpart, Wegovy, is approved for treating obesity. Both are made by Novo Nordisk. "Ozempic is the only version among the weekly ...
Studies show a doubling of NAION cases in Denmark since Ozempic's release in 2018, with annual cases rising from 60-70 to 150. The Danish Medicines Agency has reported 19 NAION cases linked to ...
Danish pharma company Novo Nordisk, makers of weight-loss drugs Ozempic and Wegovy, plans to expand production based on a takeover of US health products manufacturer Catalent, in a deal worth ...
Novo Nordisk announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use has given a positive opinion on updating the Ozempic® label to reflect data from the ...
A Scandinavian economic behemoth, Novo Nordisk is the highest-valued company in Europe at over $500 billion, which exceeds Denmark’s entire GDP. Ironically, Ozempic and Wegovy, as with many of ...
Novo Nordisk's (NVO) GLP weight-loss drug Ozempic has reportedly been linked to a rare form of vision loss, known as non-arteritic anterior ischemic optic neuropathy (NAION). The study ...
Please note that Novo Nordisk’s once-weekly subcutaneous diabetes injection, Ozempic, is already approved in 0.25 mg, 0.5 mg, 1 mg and 2 mg doses for treating T2D mellitus in adults, adjunct ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback